Abstract
Metabolomic age models have been proposed for the study of biological aging, however they have not been widely validated. We aimed to assess the performance of newly developed and existing nuclear magnetic resonance spectroscopy (NMR) metabolomic age models for prediction of chronological age (CA), mortality, and age-related disease.
98 metabolic variables were measured in blood from nine UK and Finnish cohort studies (N ≈ 31,000 individuals, age range 24-86 years). We used non-linear and penalised regression to model CA and time to all-cause mortality. We examined associations of four new and two previously published metabolomic age models, with ageing risk factors and phenotypes. Within the UK Biobank (N≈ 102,000), we tested prediction of CA, incident disease (cardiovascular disease (CVD), type-2 diabetes mellitus, cancer, dementia, chronic obstructive pulmonary disease) and all-cause mortality.
Cross-validated Pearson’s r between metabolomic age models and CA ranged between 0.47–0.65 in the training set (mean absolute error: 8-9 years). Metabolomic age models, adjusted for CA, were associated with C-reactive protein, and inversely associated with glomerular filtration rate. Positively associated risk factors included obesity, diabetes, smoking, and physical inactivity. In UK Biobank, correlations of metabolomic age with chronological age were modest (r = 0.29–0.33), yet all metabolomic model scores predicted mortality (hazard ratios of 1.01 to 1.06 / metabolomic age year) and CVD, after adjustment for CA.
While metabolomic age models were only moderately associated with CA in an independent population, they provided additional prediction of morbidity and mortality over CA itself, suggesting their wider applicability.
Competing Interest Statement
NC serves on, and get personal remuneration for Data Safety and Monitoring Boards for trials sponsored by AstraZeneca. UM reports research collaborations with Intelligent Lab on Fiber, RNA Guardian, Micronoma and MercyBio Analytics.
Funding Statement
C-H.L and OR are supported by UKRI: MR/S03532X/1; AW and NC are supported by UKRI: MC_UU_00019/1. M.A.-K. was supported by a research grant from the Sigrid Juselius Foundation, the Finnish Foundation for Cardiovascular Research, and the Research Council of Finland (grant no. 357183). J.E. is supported by UKRI/NIHR funded Multimorbidity Mechanism and Therapeutics Research Collaborative (MR/V033867/1). A.H. is supported by the UCL British Heart Foundation Accelerator (AA/18/6/34223), the UCL NIHR Biomedical Research Centre (NIHR203328), the UKRI/NIHR funded Multimorbidity Mechanism and Therapeutics Research Collaborative (MR/V033867/1) and the NIHR Senior Investigator Award NIHR202383. M. Kahonen is supported by the Clinical Chemistry and the Cancer Foundation Finland. M. Kivimaki is supported by the Wellcome Trust (221854/Z/20/Z), Medical Research Council (R024227), National Institute on Aging (R01AG062553, R01AG056477) and Academy of Finland, Finland (350426). UM receives salary support from the MRC CTU at UCL core funding (MR_UU_12023). SS received funding from the Research Council of Finland under grant number 356888. SP is supported by EU H2020, EDCMET Grant no. 825762. The Caerphilly Prospective Study (CaPS) study was undertaken by the former MRC Epidemiology Unit (South Wales) and was funded by the Medical Research Council of the United Kingdom. Phase V data were collected with funding from the Alzheimers Society. NFBC1966 received core support from University of Oulu Grants, 65354, 24000692, Oulu University Hospital Grants 2/97, 8/97, 24301140, ERDF European Regional Development Fund Grant, 539/2010 A31592. The data generation and manpower were also supported by the EU H2020 grants: LongITools (873749), EarlyCause, EDCMET (825762) and the Medical Research Council, UK: MRC/BBSRC MR/S03658X/1 (JPI HDHL H2020). The Young Finns Study has been financially supported by the Academy of Finland: grants 356405, 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 255381, 256474, 283115, 319060, 320297, 314389, 338395, 330809, and 104821, 129378 (Salve), 117797 (Gendi), and 141071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research ; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjo Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition); European Research Council (grant 742927 for MULTIEPIGEN project); Tampere University Hospital Supporting Foundation, Finnish Society of Clinical Chemistry and the Cancer Foundation Finland. SABRE was supported at baseline by the Medical Research Council, Diabetes UK and the British Heart Foundation. At follow-up the study was funded by the Wellcome Trust [grant numbers 067100, 37055891 and 086676/7/08/Z], the British Heart Foundation [grant numbers PG/06/145, PG/08/103/26133, PG/12/ 29/29497 and CS/13/1/30327] and Diabetes UK [grant number 13/ 0004774]. UKCTOCS was funded by Medical Research Council (G9901012 and G0801228), CRUK (C1479/A2884), and the Department of Health, with additional support from The Eve Appeal. The UK Medical Research Council and Wellcome (Grant ref:217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and Oliver Robinson will serve as guarantors for the contents of this paper
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for each cohort study was obtained from the Local Research Ethics Committees. Additionally, the current study was approved by the Imperial College Research Ethics Committee (Reference: 19IC5567).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
The data that support the findings of this study are available upon application to steering committee of each cohort.
Abbreviations
- NMR
- nuclear magnetic resonance
- MAE
- mean absolute error
- CI
- confidence interval
- FDR
- false discovery rate
- MARS
- multivariate adaptive regression splines
- VIF
- variable inflation factor
- VIP
- variable importance of projection
- CVD
- cardiovascular disease
- COPD
- chronic obstructive pulmonary disease
- CA
- chronological age
- BMI
- Body Mass Index
- ApoB
- Apolipoprotein B
- HDL
- high-density lipoprotein
- VLDL
- very low-density lipoprotein
- LDL
- low-density lipoprotein
- IDL
- intermediate-density lipoprotein
- TG
- triglycerides
- DHA
- docosahexaenoic acid
- SBP
- systolic blood pressure
- DBP
- diastolic blood pressure
- CRP
- C-reactive protein
- eGFR
- estimated glomerular filtration rate
- FEV1
- forced expiratory volume in first second
- UKB
- UK Biobank
- SABRE
- Southhall and Brent Revisited
- BWHHS
- British Women’s Health Heart Study
- UKCTOCS
- The Collaborative UK Ovarian Cancer Screening Trial
- WHII
- Whitehall II
- NSHD
- MRC National Survey of Health and Development
- YFS
- Young Finns Study
- NFBC1966
- The 1966 Northern Finland Birth Cohort
- CAPS
- Caerphilly Prospective Study
- ALSPAC
- Avon Longitudinal Study of Parents and Children
- UCLEB
- UCL-LSHTM-Edinburgh-Bristol Consortium
